Healthcare
Gilead Sciences, Inc.(GILD)
Live Price
Offline$123.76
-1.35% today
Window Change
-7.11%
Window
May 29, 2026 โ Jun 22, 2026
- Market Cap
- $163.61B
- Revenue Growth
- +2.4%
- EPS Growth
- +1700.0%
- Dividend Yield
- 2.4%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 29, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gilead Sciences, Inc. (GILD) is a Healthcare stock with a market cap of $163.61B and listed on NASDAQ. The stock last traded around $123.76 and down 7.1% across the available one-year price window (May 29, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of +2.4%, EPS growth of +1700.0%, a dividend yield of 2.4%. What stands out right now is revenue +2.4%, EPS +1700.0%, free cash flow -8.2% with operating margin 37.4% and ROIC 20.2%. The dividend is present but secondary, with a yield around 2.4%. Valuation sits in the middle of the pack at P/E 19.2 and price/sales 5.6. Stock Foundry combines GILD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.4% vs +7.6% peer median
Operating Margin
Above sector median
+37.4% vs +19.4% peer median
P/E
Below sector median
19.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2.4% and EPS at +1700.0%, with operating margin around 37.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
GILD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GILD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GILD Max Drawdown
-9.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GILD and SPY.
Company Overview
Gilead Sciences, Inc.
NASDAQ Global Select
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Leadership
- Daniel O'Day
- IPO Date
- Jan 22, 1992
- Employees
- 17.6k
- Street Address
- 333 Lakeside Drive
- Mailing
- Foster City, CA, 94404
- Region
- Foster City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 574 3000
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.2
- EV/EBITDA
- 14.0
- Price/Sales
- 5.6
- Price/Book
- 7.2
Growth
- Revenue
- +2.4%
- EPS
- +1700.0%
- Free Cash Flow
- -8.2%
Profitability
- Gross Margin
- 80.8%
- Operating Margin
- 37.4%
- Net Margin
- 28.9%
- ROE
- 41.0%
- ROIC
- 20.2%
Balance Sheet
- Debt/Equity
- 1.09
- Current Ratio
- 1.68
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.